新闻中心

新闻中心

News

联系我们

电话:020-34821111

传真:020-34820098

邮箱:biotech@applitechpharma.com

邮编:511422

地址:广州市番禺区兴南大道483号 华粤大厦

首页 > 新闻中心 > 公司动态 > 艾贝泰与您相约2017第九届世界疫苗/抗体大会

公司动态

艾贝泰与您相约2017第九届世界疫苗/抗体大会


今年,以“新技术,新疫苗”为主题的第九届世界疫苗大会将于2017年3月29-31日在北京万达嘉华酒店举办。组委会已邀请国际著名专家学者、著名疫苗企业高管、疾病控制部门领导等做专题报告,将围绕疫苗的政策法规、新型疫苗的研发(传染病疫苗、埃博拉疫苗、HPV疫苗、MERS疫苗、AIDS疫苗、癌症疫苗)、疫苗的生产和运输、疫苗的安全性和质量控制等展开技术讨论,并将发布最新研发成果和研发趋势,帮助企业提高研发效率,缩短研发时间,节约研发成本,加快新型疫苗上市步伐。同时,以“免疫治疗的新宠儿”为主题的世界抗体大会也于同期举行。本届大会交流内容包括抗体市场趋势、抗体的前沿研究和先进技术、抗体药物靶点、下一代抗体对癌症免疫疗法、非癌症治疗的新抗体、抗体工程和生产等。预计参会规模1000人。


疫苗和抗体的会议将在秦宫和汉宫举行。艾贝泰位于3号展位,期待您的莅临和垂询。


Chinese Forum I 中文分会一:中国抗体药物的研发
时间:2017 3 29 日(星期三)13:30-17:35,地点:北京万达嘉华酒店 5 楼秦宫
主席:胡川闽,第三军医大学医学检验系临床生物化学教研室及抗体工程实验室主任
副主席:沈月雷,百奥赛图基因生物技术公司董事长
13:30-13:35 主席介绍
13:35-14:00 题目:ADC 药物临床前评价和申报
陈春麟,上海美迪西生物医药股份有限公司首席执行官 CEO
14:00-14:25
题目:抗体开发与国际合作
白先宏,百泰生物药业有限公司董事长
14:25-14:50 题目:人源化动物在肿瘤免疫抗体药物研发中的应用
沈月雷,百奥赛图基因生物技术公司董事长
14:50-15:15 题目:临床诊断用抗体的研发与转化
胡川闽,第三军医大学医学检验系临床生物化学教研室及抗体工程实验室主任
15:15-15:30 茶歇
15:30-15:55 题目:从发现到优化,一体化平台加速抗体药物研发
殷刘松,南京金斯瑞生物科技有限公司抗体部总监
15:55-16:20 题目:新的肿瘤抗体药物靶点——纤连蛋白 B 结构域
张美,合肥立方制药股份有限公司药物研究所抗体研究室主任
16:20-16:45 题目:大规模细胞培养技术——潮汐式生物反应器
李学志,新加坡艺思高科技有限公司技术经理
16:45-17:10 题目:通量克隆筛选平台在单克隆抗体开发中的应用
艾平,美谷分子仪器(上海)有限公司高级产品经理
17:10-17:35 题目:生物反应器的关键技术及污染控制策略
刘社际,广州齐志生物工程设备有限公司副总经理
Chinese Forum II 中文分会二:细胞治疗新技术
时间:2017 3 29 日(星期三)15:30-17:35,地点:北京万达嘉华酒店 5 楼唐宫
主席:陈明伟,中国抗衰老促进会研究院副院长
15:30-15:35 主席介绍
15:35-15:55 题目:干细胞移植在抗衰老领域应用的发展趋势
陈明伟,中国抗衰老促进会研究院副院长
15:55-16:15 题目:干细胞的诱导分化
张传森,第二军医大学再生医学研究中心教授
16:15-16:35 题目:冠心病的再生医学治疗
高连如,中国北京海军总医院心脏中心主任医师
16:35-16:55 题目:基因科技与人类健康
王大伟,天津诺禾医学检验所有限公司遗传检测事业部总经理
16:55-17:15 题目:符合 GMP 要求的一站式细胞处理系统
程锦生,上海东富龙医疗装备有限公司总经理
17:15-17:35 题目:CARTISTEM-世界首创膝关节软骨再生干细胞药物
李章荣,山东源生制药有限公司董事长/韩国MEDIPOST高级总监
Chinese Forum III 中文分会三:疫苗研发与新技术
时间:2017 3 30 日(星期四)8:30-10:15,地点:北京万达嘉华酒店 5 楼汉宫
主席:柴同杰,山东农业大学教授教授、动科院教授委员会副主任
08:30-08:35 主席介绍
08:35-09:00 题目:基因工程疫苗研发中的质量控制
郑海发,北京民海生物科技有限公司总经理
09:00-09:25 题目:C 型产气荚膜梭菌类毒素疫苗对仔猪的保护研究
柴同杰,山东农业大学教授教授、动科院教授委员会副主任
09:25-09:50 题目:一类可以抵御母源抗体干扰的重组新城疫速效疫苗
尹杰超,东北农业大学生命科学学院生物制药实验室副教授
09:50-10:15 题目:题目肺炎链球菌疫苗与流感疫苗联合接种
曾光,中国疾病预防控制中心流行病学首席专家
Chinese Forum IV 中文分会四:蛋白质及抗体药物研发新进展
时间:2017 3 30 日(星期四)8:30-12:10,地点:北京万达嘉华酒店 5 楼秦宫
主席:李文凯,上海泽生科技开发股份有限公司副总经理
副主席:王露,北京大学教授
08:30-08:35 主席介绍
08:35-09:00 题目:人类功能基因组研究与转化医学
王露,北京大学教授
09:00-09:25 题目:蛋白质药物的研发策略和发展趋势
李文凯,上海泽生科技开发股份有限公司副总经理
09:25-09:50 题目:新生物活性肽组 Aglycin-Vglycin 治疗与预防糖尿病和非酒精肥胖症的药
物研究
陈正望,华中科技大学生命科学与技术学院教授
09: 50-10: 15 题目:高通量免疫基因组学分析与功能抗体发现
陈维之,金唯智中国研发总监
10:15-10:30 茶歇
10:30-10:55 题目:最新 TSKgel 抗体药物分析用色谱柱介绍
张琳,东曹(上海)生物科技有限公司技术主任
10:55-11:20 题目:上海张江生物银行—集约化样本存储公共服务平台
叶扬,上海张江生物银行运营负责人
11:20-11:45 题目:重组抑肽酶在生物制药过程的应用
李素霞,上海雅心生物技术有限公司资深科学家
11: 45-12:10 题目:IgG 样长效免疫融合蛋白的应用
胡品良,北京比洋生物技术有限公司总经理
Chinese Forum V 中文分会五:肿瘤免疫治疗新技术
时间:2017 3 30 日(星期四)13:30-16:50,地点:北京万达嘉华酒店 5 楼秦宫
主席:李大伟,上海交通大学药学院教授
副主席:李瑞强,北京诺禾致源科技股份有限公司创始人、总裁
13:30-13:35 主席介绍
13:35-14:00 题目:靶向 EGFR 的 CART 细胞治疗转移性胰腺癌的临床研究
刘洋,解放军总医院生物治疗病区老年血液科副主任医师
14:00-14:25 题目:肿瘤的精准特异性 CTL 细胞治疗和 TCR-T 细胞治疗
施炜星,上海宇研生物技术有限公司技术总监、首席科学家
14:25-14:50 题目:基因科技与产业发展
李瑞强,北京诺禾致源科技股份有限公司创始人、总裁
14:50-15:15 题目:HLA 基因扩增及过量表达对 NK 细胞杀伤活性的影响
吕有勇,北京大学临床肿瘤学院生化及生物学实验室教授、研究员
15:15-15:30 茶歇
15:30-15:55 题目:以 AGR2 旁分泌信号网络为靶点的肿瘤抗体药物
李大伟,上海交通大学药学院教授
15:55-16:20 题目:肿瘤治疗小分子药物的研发
王召印,中国科学院上海有机化学研究所研究员
16:20-16:50 小组讨论
The 9th Annual International Congress of Antibodies

Keynote Forum; Place: China Grand Ballroom 3, 5th Floor, Wanda Realm Beijing
Time: 09:10-12:00, March 29, 2017 (Wednesday)
Moderator Dr. Dan Zhang, Executive Chairman, Fountain Medical Development, Inc., China
09:10-09:35 Title: Cancer Immunotherapy: Deliver the Promise
Dr. Weikang Tao, CEO, Jiangsu Henrui Medicine Co., Ltd., R&D Centers, China
09:35-10:00 Title: Precision Xenotypic Antibodies to Enhance Cancer Treatment
Dr. Madi Madiyalakan, CEO, OncoQuest Inc., Canada
10:00-10:25 Title: Conducting MAB Trials in China: Opportunities and Challenges
Dr. Dan Zhang, Executive Chairman, Fountain Medical Development, Inc., China
10:25-10:50 Title: Genomic Neo-antigen-based Acquired Immunity Platform
Dr. Yong Qian, Chairman, BioMedicure Group, USA and China
10:50-11:00 Coffee Break
11:00-12:00 High-Level Talks Between Entrepreneurs

Segment 1: Global Antibody and Biosimilar Market Trend, Policy and Business
Session 101: Global Antibody and Biosimilar Market Trend, Policy and Business; Place: Tang
Hall, 5
th Floor, Wanda Realm Beijing
Time: 13:30-15:15, March 29, 2017 (Wednesday)
Chair Dr. Ulrich Storz, Senior Partner, Michalski Huetterman & Partner Patent
Attorneys
, USA
13:30-13:35 Chair’s Introduction
13:35-13:55 Title: The Challenge and Opportunities of Therapeutic Antibodies Development in
China - A Regulatory Perspectives
Dr. Lei Zhang, President, Biologicure Ltd., USA
13:55-14:15 Title: Regulation of Biological Medicinal Products in the European Union
Ms. Lidia Retkowska-Mika, Director, Office for Registration of Medicinal
Products,
Medical Devices and Biocidal Products, Poland
14:15-14:35 Title: Recent Developments of US Patent Laws for Antibody Drugs’ R&D
Ms. Ningling Wang, Managing Partner, Finnegan Henderson Farabow Garrett &
Dunner, LLP
, China
14:35-14:55 Title: Intellectual Property in the Antibody Space: Strategies for Startups, Pharma
and Biosimilar Manufacturers
Dr. Ulrich Storz, Senior Partner, Michalski Huetterman & Partner Patent
Attorneys
, USA
14:55-15:15 Title: Bio Similar VS. and New Drug: Clinical Development of MAB in China
Dr. Dan Zhang, Executive Chairman, Fountain Medical Development Inc., China

Segment 2: Forefront in Antibody Research and Advanced Technologies
Session 201: Forefront in Antibody Research and Advanced Technologies; Place: Tang Hall,5th
Floor, Wanda Realm Beijing
Time: 08:30-12:10, March 30, 2017(Thursday)

Chair Dr. Weiping Shao, Director, Regeneron Pharmaceuticals, Inc., USA
Co-Chair Dr. Xin Ge, Assistant Professor, University of California, Riverside, USA
08:30-08:35 Chair’s Introduction
08:35-08:55 Title: Antibody Characterization for and with Reversed Phase Protein Arrays
(RPPA)
Dr. Achim Treumann, Director, University of Newcastle, UK
08:55-09:15 Title: Immunogenicity of Biotherapeutics: Testing Strategies, Challenges and
Solutions
Dr. Weiping Shao, Director, Regeneron Pharmaceuticals, Inc., USA
09:15-09:35 Title: Antibody Protein De Novo Sequencing with LC-MS/MS
Mr. Mingjie Xie, Co-founder and CEO, Rapid Novor, Inc., Canada
09:35-09:55 Title: In-line and Real-time Prediction of Recombinant Antibody Titer by in Situ
Raman Spectroscopy
Dr. Ludovic Duponchel, Professor, University of Lille, France
09:55-10:15 Title: Generation of Highly Selective and Potent mAbs Inhibiting MMPs
Dr. Xin Ge, Assistant Professor, University of California, Riverside, USA
10:15-10:30 Coffee Break
10:30-10:50 Title: Advances in Humanized Mouse Models for Human Antibody Development
Dr. Steve Xiaofeng Yu, Director, Cyagen Biosciences, Inc. , China
10:50-11:10 Title: Novel Affinity Binders for Neutralization of VEGF Signaling
Mr. Rezan Güler, KTH, Royal Institute of Technology, Sweden
11:10-11:30 Title: Better Molecules, Faster! - Application of High Throughput Flow Cytometry
from Molecule Discovery to Early Cell Line Development
Mr. Steve Davenport, Vice President of Global Sales, Intellicyt Corporation, USA
11:30-11:50 Title: Micro Lens Imaging- New Way of Easy and Rapid Multi-pass Detection of
Ag/Ab
Dr. Yaoxiong Huang, Professor, Jinan University, China
11:50-12:10 Title: Selected Therapeutic Antibody New Method
Dr. Jiachang Yue, Professor, Institute of Biophysics, CAS, China

Segment 3: Next Generation Antibodies for Cancer Immunotherapy
Session 301: Next Generation Antibodies for Cancer Immunotherapy (Part 1); Place: Ming
Hall,5
th Floor, Wanda Realm Beijing
Time: 13:30-17:10, March 29, 2017 (Wednesday)
Chair Dr. Jason Xiang, VP and Co-founder, XDC Explorer, Inc., China
Co-Chair Dr. Qingcong Lin, Vice President, Shenogen Pharma, China
13:30-13:35 Chair’s Introduction
13:35-13:55 Title: Characterization and Conformation Studies of Antibody Drug Conjugates
Dr. Machinani Janardhan Rao, CMC Principal Consultant, Woodbury Biologics
Consulting LLC, USA
13:55-14:15 Title: ADC and Site-specific Conjugation Technology

Dr. Jason Xiang, VP and Co-founder, XDC Explorer, Inc., China
14:15-14:35 Title: A Novel ADC for CD44 Expressing Drug-resistant Non-small Cell Lung
Cancers
Dr. Jimmy Bao, Executive VP, Antibody Discovery, Abmart (Shanghai) Co., Ltd.,
China
14:35-14:55 Title: Developing and Manufacturing ADCs of the Next Generation and Its
Application in Cancer Drug Targeted Therapy
Dr. Andrew Huang, Senior VP R&D, MabPlex International Ltd, China
14:55-15:15 Title: Site-Specific Conjugation: Improving Antibody-drug Conjugate’s
Homogeneity and Their Druggability Properties
Dr. Bruce Nianhe Han, Chief Scientific Officer, NewBio Therapeutics, China
15:15-15:30 Coffee Break
15:30-15:50 Title: Lama Antibody Fragments for Imaging and Therapy
Dr. C. Theo Verrips, Former CEO, QVQ Holding b.v, The Netherlands
15:50-16:10 Title: Structural Basis of Checkpoint Blockade by Monoclonal Antibodies in Cancer
Immunotherapy
Dr. Yong-Seok Heo, Professor, Konkuk University, South Korea
16:10-16:30 Title: Tumor-penetrating Peptide Fused EGFR Single-domain Antibody Enhances
Cancer Drug Penetration into 3D Multicellular Spheroids and Facilitates Effective
Gastric Cancer Therapy
Dr. Huizi Sha, Resident, The Comprehensive Cancer Center of Drum-Tower
Hospital, Medical School of Nanjing University & Clinical Cancer
Institute of
Nanjing University
, China
16:30-16:50 Title: Gene Engineering Antibody for Future Health
Dr. Shihua Wang, Professor, Fujian Agriculture and Forestry University, China

Session 302: Next Generation Antibodies for Cancer Immunotherapy (Part 2); Place: Ming
Hall,5
th Floor, Wanda Realm Beijing
Time: 08:30-11:50, March 30,2017(Thursday)
Chair Dr. Dimiter Dimitrov, Senior Investigator, National Cancer Institute, NIH, USA
Co-Chair Dr. Wenzhi Tian, Chairman and CEO, ImmuneOnco Biopharma Co., Ltd, China
08:30-08:35 Chair’s Introduction
08:35-08:55 Title: Metastatic Gastrointestinal Cancers: Is Immunotherapy a Real Hope?
Dr. Esther Una Cidon, Medical Oncologist, Royal Bournemouth Hospital NHS
Foundation Trust, UK
08:55-09:15 Title: Simoa for the Ultra-sensitive Measurement of Proteins as Biomarkers of
Immuno-oncology Therapeutics
Dr. David C. Duffy, Vice President of Research and Chief Technology Officer,
Quanterix Corporation, USA
09:15-09:35 Title: Human Monoclonal Antibodies against Cancer and Viruses: Un Update
Dr. Dimiter Dimitrov, Senior Investigator, National Cancer Institute, NIH, USA
09:35-09:55 Title: Engineering Novel Antibody Constructs for the Treatment of Cancer and
Infectious Diseases
Dr. Tianlei Ying, Professor, Fudan University, China

09:55-10:15 Title: Development of Tumor Immunotherapeutic Products
Dr. Wenzhi Tian, Chairman and CEO, ImmuneOnco Biopharma Co., Ltd, China
10:15-10:30 Coffee Break
10:30-10:50 Title: Therapeutic Potentials of Cancer Biologics and Vaccines
Dr. Senyon Teddy Choe, Professor, University of California, USA; Director,
Mogam Biotechnology Institute, South
Korea
10:50-11:10 Title: G-MAB® Human Antibody Library Platform and Leads
Dr. Weihong Wen, Associate Professor and Vice Director, Fourth Military Medical
University, China
11:10-11:30 Title: Novel Bispecific Antibodies
Dr. Qing Li, Professor, Sun Yat-sen University, China
11:30-11:50 Title: Anti-VEGFR2-Interferon-2 Regulates the Tumor Microenvironment and
Exhibits Potent Anti-tumor Efficacy Against Colorectal Cancer
Dr. Juan Zhang, Associate Professor, China Pharmaceutical University, China

Segment 4: New Antibody for Non-cancer Therapy
Session 401: New Antibody for Non-cancer Therapy; Place: Tang Hall,5th Floor, Wanda Realm
Beijing
Time: 13:30-17:10, March 30, 2017(Thursday)
Chair Dr. Yvonne Rosenberg, President and CEO, PlantVax lnc., USA
Co-Chair Dr. Huifang Chen, Professor, University of Montreal, Canada
13:30-13:35 Chair’s Introduction
13:35-14:00 Title: Production, Pharmacokinetics, Immunogenicity and Protective Efficacy of
Plant Derived HIV Broadly Neutralizing Antibodies
Dr. Yvonne Rosenberg, President and CEO, PlantVax Inc., USA
14:00-14:25 Title: A Leaf for Life – Highly Potent Human Antibodies for Cost-effective Plant
Rabies Immune Globulin (P-RIG)
Mr. Markus Sack, RWTH Aachen University, Germany
14:25-14:50 Title: Β-Amyloid (AΒ) Autoantibodies and Alzheimer’s Disease Pathogenesis
Dr. Jun Tan, Professor, University of South Florida, USA
14:50-15:15 Title: Development of Five Hyper-humanized Antibodies Neutralizing the Botulinum
Neurotoxins A, B and E: The European Antibotabe Project
Dr. Arnaud Avril, Project Manager, Head of Antibody R&D, Institut de Recherche
Biomédicale des Armées (IRBA),
France
15:15-15:30 Coffee Break
15:30-15:55 Title: Nonhuman Primates in Biomedical and Preclinical Research
Dr. Huifang Chen, Professor, University of Montreal, Canada
15:55-16:20 Title: Changing Face of Antibody Treatment in Rheumatoid Arthritis
Dr. Syamasis Bandyopadhyay, Physician, Apollo Gleneagles Hospitals, India
16:20-16:45 Title: Anty-TNF Treatment in Spondyloarthropathy and Anti-drug Antibodies
Dr. Sundeep Kumar Upadhyaya, Senior Consultant, Apollo Gleneagles Hospitals,
India

16:45-17:10 Title: Rheumatoid Arthritis in Morocco: Study of 1400 Cases
Dr. Fatima Zahra Alaoui, Professor, University Hassan II, Morroco

Segment 5: Antibody Engineering and Production
Session 501: Antibody Engineering and Production (Part 1); Place: Ming Hall,5th Floor, Wanda
Realm Beijing
Time: 13:30-17:1 0, March 30, 2017(Thursday)
Chair Dr. Roberto Crea, President and CEO, Protelica, Inc., USA
Co-Chair Dr. Olivier Léger, Connsultant, Wuhan Institute of Biotechnology, China
13:30-13:35 Chair’s Introduction
13:35-14:00 Title: How to Speed up Your CHO and Hybridoma Screening Process – An
Automated and Targeted Way to Find and Isolate Your High-Producing Cells
Dr. Katharina Uhlig, Application Specialist, ALS Automated Lab Solutions GmbH,
Germany
14:00-14:25 Title: Antibody Engineering for Therapeutic Use: Focus on Sequence Optimization
Strategies
Dr. Olivier Léger, Connsultant, Wuhan Institute of Biotechnology, China
14:25-14:50 Title: Pronectins™, a New Class Of Antibody Mimics for Cancer
Immunotherapeutic Applications
Dr. Roberto Crea, President and CEO, Protelica, Inc., USA
14:50-15:15 Title: Orbital Shaken Bioreactors: The Scale up Fast Track (from mL to 2500L)
Dr. Tibor Anderlei, Director of Sales and Business Development, Adolf Kühner AG,
Switzerland
15:15-15:30 Coffee Break
15:30-15:55 Title: Nanobody Based Immunoassays for Food and Environmental Chemicals
Dr. Zhenlin Xu, Associate Professor, South China Agricultural University, China
15:55-16:20 Title: Switchable Membrane Reporter (Swimr) Technology for Recombinant Protein
Expression and Protein Engineering
Dr. Bo Yu, Founder and CSO, Larix Bioscience LLC, USA
16:20-16:45 Title: Faster – Leaner – Smarter: Trends in Bio-manufacturing Process Design
Mr. Ruediger Mechsner, Principal Consultant, Samsung Engineering, South Korea
16:45-17:10 Title: Computational Assisted Production of Antibody with Ideal Character
Dr. Cunzheng Zhang,
Research Professor, Institute of Food safety of Jiangsu
Academy of Agricultural Sciences
, China

Session 502: Antibody Engineering and Production (Part 2); Place: Tang Hall,5th Floor, Wanda
Realm Beijing
Time: 08:30-11:50, March 31, 2017(Friday)
Chair Dr. Boaz Tirosh, Associate Professor, The Hebrew University of Jerusalem, Israel
Co-Chair Dr. Dennis Lin, Associate Principal Scientist, Mycenax Biotech Inc., Taiwan
08:30-08:35 Chair’s Introduction

08:35-08:55 Title: Innovative Methods for Host-residual DNA Impurity Quantification in
Biologics
Dr. Musaddeq Hussain, Principal Scientist, Merck Research Laboratories, USA
08:55-09:15 Title: Design of Safety Measures in Production Processes
Dr. Rolf G. Werner, Professor, University of Tuebingen, Germany
09:15-09:35 Title: Overcoming Translation Bottlenecks for Improved Antibody Production in
Mammalian Cells
Dr. Boaz Tirosh, Associate Professor, The Hebrew University of Jerusalem, Israel
09:35-09:55 Title: Rabmab Application in Sandwich ELISA and Multiplex Assay
Ms. Xingmei Tan, Senior Engineer, Abcam Hangzhou, China
09:55-10:15 Title: Upstream Process Development Module and Quality Optimization of
Therapeutic Mab
Dr. Dennis Lin, Associate Principal Scientist, Mycenax Biotech Inc., Taiwan
10:15-10:30 Coffee Break
10:30-10:50 Title: Biologicals in China: Factors Affecting Quality and Sustainability
Mr. Loany Calvo Gonzalez, Senior Director, Bio-Thera Solutions, China
10:50-11:10 Title: Bioinspired Design of Affinity Peptide Ligands for Antibody Based on Protein
a Affinity Motif
Dr. Fufeng Liu, Professor, Tianjin University of Science & Technology, China
11:10-11:30 Title: The Simoa HD-1 Analyzer: A Fully-automated, Multiplexed Immunoanalyzer
with Single Molecule Sensitivity
Dr. David C. Duffy, Vice President of Research and Chief Technology Officer,
Quanterix Corporation, USA
11:30-11:50 Title: Solving Production Challenges of Antibody-based Biologics with a Scalable,
Continuous Manufacturing Bioreactor
Mr. Scott Waniger, Vice President, C3 Culture Company, USA

The 9th Annual World Congress of Vaccine-2017
Pipeline 1: Vaccine R&D and New Technologies
Session 101: Vaccine R&D and New Technologies (Part 1)
Time: 13:30-16:45, March 29, 2017 (Wednesday); Place: Han Hall,5th Floor, Wanda Realm Beijing
Chair Dr. Michel Klein, CSO, VaxiBio, China
Co-chair Dr. Rajesh K. Gupta, Co-owner & Principal Consultant, Biologics Quality &
Regulatory Consultants, LLC, USA
13:30-13:35 Chair’s Introduction
13:35-14:00 Keynote speaker
Title:
Building Quality During Manufacture of Vaccines – Quality by Design (QbD),
Product Life Cycle and Modern Technologies/Methods
Dr. Rajesh K. Gupta, Co-owner & Principal Consultant, Biologics Quality &
Regulatory Consultants, LLC, USA
14:00-14:25 Title: Vaccinomics in the Next Century

Dr. Michel Klein, CSO, VaxiBio, China
14:25-14:50 Title: QS-21: A Potent Vaccine Adjuvant
Dr. Daming Zhu, Head of Quality Control Unit, NIAID/NIH, USA
14:50-15:15 Title: Novel Adjuvant L-pampo and Development of Improved HBV Vaccines
Dr. Jung Sun Yum , Executive Director, CHA Vaccine Institute, Korea
15:15-15:30 Coffee Break
15:30-15:55 Title: Online Measurements of Viable and Total Cell Densities
Mr. Jochen Uhlenküken, Business Development Manager, Hamilton Bonaduz AG,
Switzerland
15:55-16:20 Title: Balance Between Crystalline and Amorphous Excipients in Lyophilization and
Spray-drying Formulation Development
Dr. Tom H Jin, Senior Scientist, IDT Biologika, USA
16:20-16:45 Title: Immunoproteomics for Antigen/Epitope Screening Against Human Infections
Dr. Kokouvi Kassegne, National Institute of Parasitic Diseases, Chinese Centre
for Disease Control and Prevention
, China

Session 102: Vaccine R&D and New Technologies (Part 2)
Time: 10:30-12:15, March 30,2017(Thursday) ; Place: Han Hall,5th Floor, Wanda Realm Beijing
Chair Dr. Luis Martin, CEO, Pan-Provincial Vaccine Enterprise (PREVENT), Canada
10:30-10:35 Chair’s Introduction
10:35-11:00 Title: Novel Strategies for Vaccine Development and Cancer Therapy: A Theory of
Intact or Protected Complement (IPC) Immunity
Dr. Tom H. Jin, Senior Scientist, IDT Biologika, USA
11:00-11:25 TitleUnmet Medical Needs: Where and How Can Innovation Help?
Dr. Luis Martin, CEO, Pan-Provincial Vaccine Enterprise (PREVENT), Canada
11:25-11:50 Title: Serotype Distribution and Penicillin Resistance of Streptococcus Pneumoniae
in Kuwait: A Ten-year Study of Impact of Pneumococcal Conjugate Vaccines
Dr. Eiman Mokaddas, Professor, Kuwait University, Kuwait
11:50-12:15 Title: Typhoid Conjugate Vaccines Development
Dr. Viliam (Vilo) Pavliak, Head of Vaccine Development, International Vaccine
Institute, Korea

Pipeline 2: Human Vaccines for Major Diseases
Session 201: Human Vaccines for Major Diseases ; Place: Han Hall,5th Floor, Wanda Realm Beijing
Time: 13:30-16:45, March 30, 2017(Thursday)
Chair Dr. Armando Zuniga, CSO, Virometix AG, Switzerland
13:30-13:35 Chair’s Introduction
13:35-14:00 Title: Synthetic Virus-like Particles (SVLPs) for the Development of Peptide-based
Cancer Vaccines
Dr. Armando Zuniga, CSO, Virometix AG, Switzerland

14:00-14:25 Title: Targeted Vaccination and Intrinsic Adjuvant Function: Next Generation
Checkpoint Control
Dr. Geert. C. Mudde, CSO and Managing Director, OncoQR ML GmbH, Austria
14:25-14:50 Title: Next Generation Influenza Vaccines: Challenges and Recent Developments
Dr. Yuri M. Vasiliev, Deputy Director for Science, St. Petersburg Research Institute
for Vaccines and Sera, Russia
14:50-15:15 Title: TB Vaccines: Challenges and Approaches
Ms. Molly (Miao) Zhang, Project Coordinator, AERAS, China
15:15-15:30 Coffee Break
15:30-15:55 TitleThe Impact of the Emerging Diseases In HIV Infection. Can We Prevent
Them?
Dr. Gustavo A. Echenique, Head of Infectious Diseases, Tropical and Infectious
Diseases Unit “Nuestra Señora del Rosario” Clinic, Argentina
15:30-15:55 Title: Clinical Study of Cancer Vaccine-points to Consider in Trial Design
Dr. Lei Zhang, President, Biologicure Ltd., USA

Pipeline 3: Veterinary Vaccines and Vaccines Production
Session 301: Veterinary Vaccines; Place: Han Hall,5th Floor, Wanda Realm Beijing
Time: 08:30-11:20, March 31, 2017(Friday)
Chair Dr. Andrew A. Potter, Director, University Of Saskatchewan, Canada
08:30-08:35 Chair’s Introduction
08:35-09:00 Title: The Application of Three Antigenic Formulas Contaning Selected
Recombinant Outer Membrane Proteins and LPS Core from Gram Negative Bacteria
in Dairy Calves
Dr. Tadeusz Stefaniak, Professor, Wroclaw University of Environmental and Life
Sciences, Poland
09:00-09:25 Title: The Evaluation of Three Subunit Vaccines Formulas Containing Recombinant
Outer Membrane Proteins and LPS Core Conjugate in Piglets
Ms. Anna Rzasa, Associate Professor, Wroclaw University of Environmental and
Life Sciences, Poland
09:25-09:50 Title: Vaccines for Foot and Mouth Disease (FMD) Specific Prevention in Farm
Animals. Review of Preparations Manufactured in FGBI “ARRIAH”
Dr. Artem Metlin, Deputy Director, FGBI “ARRIAH”, Russia
09:50-10:15 Title: Challenges Faced by Uruguay and South America under the Hemispheric
Program for the Eradication of Foot and Mouth Disease
Dr. Jiechao Yin, Northeast Agricultural University, China
10:15-10:30 Coffee Break
10:30-10:55 Title: Modelling and Optimizing Alternating Tangential Flow Filtration for
Perfusion Cellculture
Dr. William J. Kelly, Professor, Villanova University, USA
10:55-11:20 Title: Technology Innovations for Large Scale Cell Expansion
Dr. Huadong Liu, Field Application Scientist, Corning Life Sciences, China